Kineta, Inc/de 8-K filings

TuHURA Biosciences, Inc. has successfully completed its acquisition of Kineta, Inc., integrating Kineta's novel VISTA inhibiting antibody, TBS-2025, into its late-stage immuno-oncology pipeline and unlocking a $12.5 million aggregate PIPE financing tranche.

Kineta, Inc. and TuHURA Biosciences, Inc. stockholders have overwhelmingly approved the proposed merger and related proposals, signaling a significant step towards combining their immuno-oncology development efforts.

Kineta, Inc. and TuHURA Biosciences, Inc. have amended their merger agreement, modifying the per share consideration and extending the end date to June 30, 2025, pending a minimum $20 million concurrent investment in TuHURA.

Kineta Inc. announces the resignation of Marcum LLP as its independent auditor and the engagement of CBIZ CPAs, effective March 27, 2025.

Kineta, Inc. exchanges existing warrants for common stock and a pre-funded warrant with Armistice Capital Master Fund Ltd.

Kineta, Inc. reports the termination of the GigaGen agreement and the sale of assets related to KCP506 and other intellectual property as part of its merger agreement with TuHURA Biosciences, Inc.

TuHURA Biosciences has entered into a definitive agreement to acquire Kineta, gaining access to a promising Phase 2 checkpoint inhibitor, KVA12123, and expanding its oncology pipeline.

TuHURA Biosciences and Kineta, Inc. have entered into a non-binding letter of intent for TuHURA to potentially acquire Kineta's KVA12123 VISTA inhibiting antibody.

Kineta's VISTA-101 Phase 1/2 clinical trial shows encouraging results for KVA12123, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Kineta has completed enrollment in the monotherapy arm of its Phase 1 VISTA-101 clinical trial for advanced solid tumors and is progressing with combination therapy studies.

Kineta, Inc. announced that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting.

Kineta, Inc. has announced that TuHURA Biosciences has exercised its option to extend their exclusivity and right of first offer agreement for Kineta's VISTA blocking antibody, KVA12123.

Kineta, Inc. has moved its stock listing from the Nasdaq Capital Market to the OTC Pink Open Market due to non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements.

Kineta, Inc. will be delisted from the Nasdaq Capital Market due to non-compliance with listing rules and will begin trading on the OTC Markets Group platform on September 19, 2024.

Kineta, Inc. is facing potential delisting from the Nasdaq due to non-compliance with listing rules and has entered into a settlement agreement to resolve outstanding lease obligations.

Kineta has resumed enrollment in its VISTA-101 Phase 1/2 clinical trial for KVA12123, a VISTA blocking immunotherapy, after a temporary suspension due to funding issues.

Kineta has granted TuHURA Biosciences an exclusive right to negotiate the acquisition of its KVA12123 immunotherapy program, receiving a $5 million nonrefundable payment.

Kineta, Inc. held its 2024 Annual Meeting of Stockholders on June 21, 2024, where key proposals including the election of directors and ratification of the accounting firm were approved.

Kineta, Inc. received a notice from Nasdaq for failing to maintain the minimum stockholders' equity requirement for continued listing.

Kineta announced its first quarter 2024 financial results, provided an update on its VISTA-101 clinical trial, and disclosed it is exploring strategic alternatives due to funding challenges.

Kineta Inc. reached a settlement with RLB Holdings regarding a prior investment agreement and received a notice from Nasdaq for failing to maintain the minimum bid price.

Kineta, Inc. has implemented a new stock award and cash retention plan to incentivize and retain key executives, including the President, CFO, and CSO.

Kineta reported positive initial clinical response data from its Phase 1/2 VISTA-101 trial, showing partial responses and stable disease in patients with advanced solid tumors.

Kineta reported its 2023 financial results, highlighted by a significant reduction in net loss, but also announced a corporate restructuring and exploration of strategic alternatives due to funding issues.

Kineta, Inc. announced a corporate restructuring, including a significant workforce reduction and the suspension of new patient enrollment in its VISTA-101 clinical trial, while also exploring strategic alternatives to maximize shareholder value.

Kineta, Inc. is implementing a significant restructuring, including a 64% workforce reduction and halting new patient enrollment in a clinical trial, as it explores strategic alternatives due to a funding shortfall.

Kineta's Phase 1/2 clinical trial of KVA12123 in advanced solid tumors demonstrates a favorable safety profile and dose-proportional induction of pro-inflammatory biomarkers.